Ardian, Charterhouse, CVC and L Catterton are among the PE firms investing in different areas of the women's healthcare market. The post [PE delves into diverse women’s health segments: 6 deals](https://www.pehub.com/pe-delves-into-diverse-womens-health-segments-6-deals/) appeared first on [PE Hub](https://www.pehub.com).

Women's health, encompassing reproductive care, metabolic conditions, and chronic diseases, has seen fragmented investment despite representing 6% of private healthcare capital flows. The World Economic Forum's 2024 report revealed 90% of women's health investments focus on reproductive health and cancer, leaving cardiovascular and mental health underfunded. This gap creates opportunities for PE firms targeting underserved segments.

Recent deals highlight sector diversity. CVC-backed FutureLife acquired the UK's Herts & Essex Fertility Centre, expanding its 16-country footprint. Ardian secured a minority stake in Spain's IVB Wellness Lab to advance metabolic health solutions. Verdane became Clue's largest investor, scaling its period-tracking app with 100 million downloads. Charterhouse partnered with Winback for non-invasive therapies used in 55 countries, while L Catterton reinforced US Fertility's physician-led network. Salt Creek Capital acquired Real Diagnostics, a women's health diagnostics lab operating across 17 states.

These transactions reflect growing institutional confidence in women's health as a high-growth market. Dealmakers cite strong cashflow potential and demographic tailwinds, with US Fertility's CV-on-CV process targeting $500 million in new capital. As awareness of gender-specific health disparities rises, PE firms are positioning themselves to address both clinical needs and financial returns.